The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with gemcitabine and cisplatin chemotherapy as a neoadjuvant treatment before bladder ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...

Small cell lung cancer (SCLC) accounts for 10-15% of all lung cancer cases annually, with 250,000 incident cases diagnosed ...

Three more fake batches of the cancer immunotherapy have been encountered in Iran and Türkiye, warns the agency.

Over the last week, AstraZeneca's share price increased by 1%, aligning closely with the broader market's growth of 2%. While ...

(Alliance News) - AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free ...